The Rs 4,326.36 crore initial public offer (IPO) of Mankind Pharma has been subscribed by 56% on the day of the offer by 3.45 PM. The issue received bids for 1,57,57,950 equity against 2,80,41,192 equity shares. Click here to subscribe the IPO.
High net-worth individuals (HNIs) have bought 77% shares against the quota reserved for them, while qualified institutional buyers (QIBs) quota received 1.03 times bid, so far, against shares reserved for them. Retail investors have bid for 21% of the share set aside for them.
As the IPO is an offer for sale, the company will not receive any net proceeds.
Kotak Mahindra Capital Company, Axis Capital, IIFL Capital Services, Jefferies India and JP Morgan India are the lead managers to the issue.
The equity shares of the company will be listed on May 9 on both BSE and NSE.
Mankind Pharma IPO important details
Open date | April 21 |
Close date | April 25 |
Lot size | 13 |
IPO size (Rs crore) | Rs 4,326.36 Cr |
IPO price range (Rs) | Rs 1026-1080 per share |
Minimum investment | Rs 14,040 |
Basis of allotment date | April 28 |
Refunds date | May 2 |
Credit to demat account date | May 3 |
Listing date | May 4 |
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.